尼达尼布抗器官纤维化研究进展

Research Progress of Nintedanib Against Organ Fibrosis

纤维化疾病是指各种原因引起的组织损伤后的异常修复导致正常组织被富含胶原的疤痕组织取代引起结构变形,最终导致器官功能衰竭和消失的一类疾病。尼达尼布是1种酪氨酸激酶抑制剂,被证实具有明显的抗纤维化作用。笔者总结尼达尼布抗各种器官纤维化的国内外分子机制研究,包括已获批的特发性肺纤维化、系统性硬化症相关间质性肺病和进展性纤维化性间质性肺病,以及尚处于临床前的肝纤维化、肾纤维化和心肌纤维化,并简要总结了已获批适应证的临床结果。以期可以为进一步研究尼达尼布在治疗其他纤维化疾病中的应用提供参考。

Fibrotic disease refers to a type of disease in which abnormal repair after tissue damage caused by various factors causes normal tissue to be replaced by collagen-rich scar tissue,causing structural deformation,and ultimately leading to organ malfunction and death.Nintedanib is a tyrosine kinase inhibitor that has been proven to have obvious anti-fibrotic effects.This article summarizes the domestic and foreign molecular mechanism research of nintedanib against various organ fibrosis,including approved idiopathic pulmonary fibrosis,systemic sclerosis-related interstitial lung disease(SSc-ILD)and progressing fibrotic interstitial lung disease(PF-ILD),as well as preclinical liver fibrosis,renal fibrosis and myocardial fibrosis,and briefly summarizes the clinical results of the approved indications.This review can provide a reference for further research on the application of nintedanib in the treatment of other fibrotic diseases.